**Study Title: Understanding the Impact of Proactive Management to Improve Symptomatic Contact Lens Wearers Success**

Participants

Screened n= 87

Screen failures = 6

Enrolled n= 81

Lost to follow-up = 8

Included in Analysis n= 73

Baseline Characteristics

**Table 1 - Gender and Age of Study Population**

|  |  |
| --- | --- |
|  | **Overall** |
| **N** | 73 |
| **Gender** |  |
| Female |  59(81%) |
| Male |  14(19%) |
| **Age** |  |
| Mean | 26.8 |
| Std. Dev | 5.7 |

Outcome Measures

*Primary Outcome Measure – CLDEQ8 Score*

**Table 2 – CLDEQ8 Score at Follow-up**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** |  | **Baseline** | **1M** | **3M** | **6M** | **12M** |
| **Test** | **N** | 34 | 34 | 34 | 34 | 34 |
| **Mean** | 17.8 | 12.5 | 13.0 | 9.6 | 9.9 |
| **Std. Deviation** | 6.5 | 5.7 | 6.0 | 5.4 | 6.2 |
| **Control** | **N** | 36 | 36 | N/A  | 36 | 36 |
| **Mean** | 18.9 | 11.6 |   | 10.8 | 11.1 |
| **Std. Deviation** | 4.6 | 6.6 |   | 6.2 | 7.3 |

*Primary Outcome Measure – Contact Lens Wearing Time*

**Table 3 – Contact Lens Wearing Time (hours)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** |  | **Baseline** | **1M** | **3M** | **6M** | **12M** |
| **Test** | **N** | 34 | 34 | 34 | 34 | 34 |
| **Mean** | 7.1 | 9.3 | 9.6 | 9.6 | 9.5 |
| **Std. Deviation** | 2.9 | 2.9 | 3.0 | 2.8 | 3.1 |
| **Control** | **N** | 36 | 36 | N/A  | 36 | 36 |
| **Mean** | 7.6 | 9.1 |   | 9.4 | 9.5 |
| **Std. Deviation** | 2.3 | 2.8 |   | 3.0 | 3.3 |

*Secondary Outcome Measure – Comfort*

**Table 4 - Contact Lens Overall Comfort (100-point VAS)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** |  | **Baseline** | **1M** | **3M** | **6M** | **12M** |
| **Test** | **N** | 34 | 33 | 33 | 33 | 34 |
| **Mean** | 60.6 | 82.6 | 78.3 | 86.2 | 82.5 |
| **Std. Deviation** | 15.7 | 14.4 | 19.1 | 12.2 | 16.5 |
| **Control** | **N** | 35 | 34 | N/A  | 35 | 36 |
| **Mean** | 60.7 | 75.6 |   | 83.7 | 82.7 |
| **Std. Deviation** | 15.0 | 18.2 |   | 16.7 | 18.7 |

Adverse Events

**Table 4 – Adverse Events**

|  |  |  |
| --- | --- | --- |
| **Number of participants affected** | **Event** | **Status** |
| 1 | **Skin Cyst** | Resolved |
| 12 | **Cold** | All Resolved |
| 1 | **Throat Infection** | Resolved |
| 1 | **Vitamin D Deficiency** | Resolved |
| 1 | **Gastroenteritis** | Resolved |
| 2 | **Flu** | Resolved |
| 2 | **Toothache** | Resolved |
| 2 | **Conjunctivitis** | Resolved |
| 1 | **Right Sub-Conjunctival Haemorrhage**  | Resolved |
| 1 | **Fractured Toes** | Resolved |
| 1 | **Worsening Ocular Symptoms** | Resolved |
| 1 | **Suspect COVID-19** | Resolved |
| 1  | **Viral Conjunctivitis** | Resolved |
| 1 | **Face Oedema** | Resolved |
| 1 | **Sprained Ankle** | Resolved |
| 1  | **Skin Allergic Reaction** | Resolved |
| 1 | **Sinus Infection**  | Resolved |
| 1 | **Ear Infection** | Resolved |
| 1 | **Kidney Infection** | Resolved |
| 2 | **Suspect Ocular Foreign Body** | Resolved |
| 1 | **Corneal Scar** | Resolved |